Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 pounds
09:15am, Thursday, 27'th Apr 2023
Eli Lilly plans to complete its application for FDA approval of tirzepatide in the coming weeks and expects regulatory action as early as later this year.
Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water
08:57am, Thursday, 27'th Apr 2023
Eli Lilly stock jumped Thursday on better-than-expected sales of diabetes newcomer, Mounjaro, helping offset a massive Covid-related decline. The post Eli Lilly's Diabetes Newcomer, Mounjaro, Just Ble
Eli Lilly misses on earnings but raises full-year guidance
08:07am, Thursday, 27'th Apr 2023
The company reported adjusted earnings of $1.62, which missed analyst expectations of $1.73 for the quarter.
Eli Lilly stock up premarket as company's Q1 revenue beats and it raises guidance
07:01am, Thursday, 27'th Apr 2023
Eli Lilly & Co. shares LLY rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance. The company posted net income of $1.345
Eli Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in late-stage trial
06:25am, Thursday, 27'th Apr 2023
Eli Lilly & Co. LLY said Thursday its tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in a late-stage trial. Participants in the phase 3 trial cal
Eli Lilly's Mounjaro Moves Toward Possible FDA Obesity Approval
06:15am, Thursday, 27'th Apr 2023
The company plans to finalize its application for FDA approval of its weight-loss drug tirzepatide, sold as Mounjaro.
Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings
07:46pm, Wednesday, 26'th Apr 2023
Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.
Eli Lilly Earnings Are Soon. All Eyes Are on Its Diabetes Drug.
04:30pm, Wednesday, 26'th Apr 2023
Expectations for first-quarter sales of its diabetes treatment, Mounjaro, are $433 million.
Why Eli Lilly Stock Is Under Pressure Today
01:20pm, Wednesday, 26'th Apr 2023
Eli Lilly is scheduled to report 2023 Q1 earnings tomorrow. Investors seem to be concerned that Wall Street's expectations are too high.
Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More
10:40am, Wednesday, 26'th Apr 2023
Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.
Why Earnings Season Could Be Great for Eli Lilly (LLY)
09:54am, Wednesday, 26'th Apr 2023
Eli Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer's drug space, CEO says
01:40pm, Tuesday, 25'th Apr 2023
Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.
2 Monster Stocks to Buy Without Any Hesitation
10:20am, Tuesday, 25'th Apr 2023
Eli Lilly's shares are up more than 235% over the past five years. Mounjaro is expected to be a blockbuster drug for Lilly.
Better Buy: Novo Nordisk vs. Eli Lilly
05:17am, Tuesday, 25'th Apr 2023
Sales of Novo Nordisk's diabetes drug and weight-management drugs are soaring. Eli Lilly's popular new diabetes drug, Mounjaro, could soon earn approval to address chronic weight management.
Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In The Red-Hot Obesity Shot Race
01:13pm, Monday, 24'th Apr 2023
Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment. The post Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In The
